Chemed Co. (NYSE:CHE) Director Donald E. Saunders bought 94 shares of the firm’s stock in a transaction on Thursday, May 4th. The stock was purchased at an average price of $205.59 per share, with a total value of $19,325.46. Following the completion of the acquisition, the director now owns 9,886 shares of the company’s stock, valued at $2,032,462.74. The purchase was disclosed in a filing with the SEC, which is available through this link.
Shares of Chemed Co. (NYSE:CHE) traded up 0.068% during midday trading on Friday, hitting $197.445. 48,576 shares of the stock traded hands. The company has a market capitalization of $3.18 billion, a PE ratio of 28.968 and a beta of 1.21. Chemed Co. has a 12-month low of $126.54 and a 12-month high of $216.01. The firm’s 50 day moving average price is $193.08 and its 200 day moving average price is $171.39.
Chemed (NYSE:CHE) last issued its earnings results on Wednesday, April 26th. The company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.04. Chemed had a return on equity of 23.95% and a net margin of 6.77%. The firm had revenue of $405.90 million for the quarter, compared to analyst estimates of $399.75 million. During the same period in the previous year, the company posted $1.62 earnings per share. The business’s revenue was up 4.0% on a year-over-year basis. Analysts expect that Chemed Co. will post $7.95 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 14th. Investors of record on Thursday, May 25th will be paid a dividend of $0.26 per share. The ex-dividend date is Tuesday, May 23rd. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.53%. Chemed’s payout ratio is 16.59%.
Hedge funds have recently added to or reduced their stakes in the stock. Van Berkom & Associates Inc. raised its stake in Chemed by 5.8% in the third quarter. Van Berkom & Associates Inc. now owns 474,136 shares of the company’s stock worth $66,886,000 after buying an additional 26,040 shares during the last quarter. Capital Fund Management S.A. raised its stake in Chemed by 7.9% in the third quarter. Capital Fund Management S.A. now owns 33,450 shares of the company’s stock worth $4,719,000 after buying an additional 2,442 shares during the last quarter. New Amsterdam Partners LLC NY raised its stake in Chemed by 29.7% in the third quarter. New Amsterdam Partners LLC NY now owns 27,017 shares of the company’s stock worth $3,811,000 after buying an additional 6,189 shares during the last quarter. Sei Investments Co. raised its stake in Chemed by 14.4% in the third quarter. Sei Investments Co. now owns 4,627 shares of the company’s stock worth $653,000 after buying an additional 582 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in Chemed by 13.1% in the third quarter. TIAA CREF Investment Management LLC now owns 107,496 shares of the company’s stock worth $15,164,000 after buying an additional 12,474 shares during the last quarter. Institutional investors own 99.72% of the company’s stock.
Separately, Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $195.00 price target on the stock in a report on Monday, February 20th.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Co. and related companies with MarketBeat.com's FREE daily email newsletter.